ZA931585B - Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use. - Google Patents

Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use.

Info

Publication number
ZA931585B
ZA931585B ZA931585A ZA931585A ZA931585B ZA 931585 B ZA931585 B ZA 931585B ZA 931585 A ZA931585 A ZA 931585A ZA 931585 A ZA931585 A ZA 931585A ZA 931585 B ZA931585 B ZA 931585B
Authority
ZA
South Africa
Prior art keywords
biphenylsulfonylurethane
biphenylsulfonylurea
preparation
side chain
imidazole derivatives
Prior art date
Application number
ZA931585A
Other languages
English (en)
Inventor
Holger Heitsch
Adalbert Wagner
Reinhard Becker
Rainer Henning
Hermann Gerhards
Bernward Schoelkens
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA931585B publication Critical patent/ZA931585B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA931585A 1992-03-07 1993-03-05 Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use. ZA931585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4207241 1992-03-07

Publications (1)

Publication Number Publication Date
ZA931585B true ZA931585B (en) 1993-09-27

Family

ID=6453463

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA931585A ZA931585B (en) 1992-03-07 1993-03-05 Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain, process for their preparation and their use.

Country Status (25)

Country Link
US (1) US5604251A (fr)
EP (1) EP0560177B1 (fr)
JP (1) JP3542813B2 (fr)
KR (1) KR930019637A (fr)
CN (1) CN1036341C (fr)
AT (1) ATE230732T1 (fr)
AU (1) AU663565B2 (fr)
BR (1) BR9300761A (fr)
CA (1) CA2091135A1 (fr)
CZ (1) CZ281983B6 (fr)
DE (1) DE59310323D1 (fr)
DK (1) DK0560177T3 (fr)
ES (1) ES2187501T3 (fr)
FI (1) FI930970A7 (fr)
HU (1) HUT64041A (fr)
IL (1) IL104971A0 (fr)
MA (1) MA22814A1 (fr)
NO (1) NO303632B1 (fr)
NZ (1) NZ247059A (fr)
PH (1) PH31466A (fr)
PL (1) PL173023B1 (fr)
RU (1) RU2116300C1 (fr)
SK (1) SK279109B6 (fr)
TW (1) TW215434B (fr)
ZA (1) ZA931585B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
EP0904077A4 (fr) 1996-02-20 1999-12-22 Bristol Myers Squibb Co Procedes d'elaboration de biphenyl isoxazole sulfamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
CA2274789A1 (fr) * 1996-12-13 1998-06-18 Zymogenetics, Inc. Compositions visant a stimuler la croissance osseuse et methodes afferentes
EP0855392A3 (fr) 1997-01-22 2000-01-05 Hoechst Aktiengesellschaft Hétérocycles à cinq chaínons contenant des substituants biphénylylsulphoniques, leur procédé de préparation, leur utilisation comme médicament ou agent diagnostique ainsi que médicament les contenant
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998033781A1 (fr) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Procede pour prevenir ou traiter l'hypertension due a une baisse de secretion de la renine, par l'administration d'un antagoniste de l'endotheline
WO1999019471A1 (fr) 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Modeles et traitement de l'hypertrophie cardiaque en liaison avec la fonction nf-at3
DE19802969A1 (de) 1998-01-27 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von S-Alkyl(Aryl)-substituierten Imidazol-Derivaten
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
US20040106647A1 (en) * 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
WO2004002226A1 (fr) * 2002-06-28 2004-01-08 Baylor College Of Medicine Modulateurs de cdk9 utilises comme cible therapeutique dans l'hypertrophie cardiaque
EP1631268A2 (fr) * 2003-05-21 2006-03-08 Board Of Regents The University Of Texas System Inhibition de la proteine kinase c-mu (pkd) dans le traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP2007510727A (ja) * 2003-11-03 2007-04-26 ミオゲン インコーポレイティッド 心血管疾患を治療するための１，４−ジヒドロピリジン化合物、薬学的組成物、および方法
JP2007510728A (ja) * 2003-11-03 2007-04-26 ミオゲン インコーポレイティッド 心血管疾患を治療するための１，４−ジヒドロピリジン化合物、薬学的組成物、および方法
US20060018970A1 (en) * 2003-12-12 2006-01-26 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
CA2560538A1 (fr) * 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxyde et son utilisation dans le traitement de maladies induites par pde-iii
EP1737448A1 (fr) * 2004-03-22 2007-01-03 Myogen, Inc. Sulfoxyde de (s)-enoximone et son utilisation dans le traitement de maladies mediees par pde-iii
EP1776108A1 (fr) * 2004-06-23 2007-04-25 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
CA2592900A1 (fr) 2005-01-03 2006-07-13 Myriad Genetics Inc. Composes et utilisation therapeutique associee
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1945242A2 (fr) * 2005-07-22 2008-07-23 The Regents of the University of Colorado, A Body Corporate Inhibition de la kinase erk 1/2 ("extracellular signal-regulated kinase") servant a traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
JP2009520833A (ja) * 2005-12-20 2009-05-28 ギリード・コロラド・インコーポレーテッド ４，７−ジヒドロチエノ［２，３−ｂ］ピリジン化合物及び医薬組成物
KR101485495B1 (ko) 2006-08-01 2015-01-22 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정
AU2008283795B2 (en) 2007-07-31 2013-11-21 Board Of Regents, The University Of Texas System A micro-RNA family that modulates fibrosis and uses thereof
CA2718520C (fr) 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification des micro-arn dans l'entretien et la regeneration de synapses neuromusculaires
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
GB2605148A (en) * 2021-03-23 2022-09-28 Vicore Pharma Ab New compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
CA1334092C (fr) * 1986-07-11 1995-01-24 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii
US5138069A (en) * 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
SU1518949A1 (ru) * 1987-04-09 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения инъекционного раствора 5-этокси-2-этилтиобензимидазола
CA1338238C (fr) * 1988-01-07 1996-04-09 David John Carini Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
US5135197A (en) * 1990-08-30 1992-08-04 Qualtec Data Products, Inc. Equipment security method and apparatus
US5126342A (en) * 1990-10-01 1992-06-30 Merck & Co., Inc. Imidazole angiotensin ii antagonists incorporating acidic functional groups
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
CA2058198A1 (fr) * 1991-01-04 1992-07-05 Adalbert Wagner Procede de preparation et utilisation de derives d'azole
US5236928A (en) * 1991-03-19 1993-08-17 Merck & Co., Inc. Imidazole derivatives bearing acidic functional groups at the 5-position, their compositions and methods of use as angiotensin II antagonists
WO1993004045A1 (fr) * 1991-08-19 1993-03-04 E.I. Du Pont De Nemours And Company Derives d'imidazolinone d'inhibition de l'action de l'angiotensine ii sur ses recepteurs
DE4221009A1 (de) * 1992-06-26 1994-01-05 Bayer Ag Imidazolyl-substituierte Cyclohexanderivate
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения

Also Published As

Publication number Publication date
ATE230732T1 (de) 2003-01-15
FI930970A7 (fi) 1993-09-08
DE59310323D1 (de) 2003-02-13
JPH069572A (ja) 1994-01-18
FI930970A0 (fi) 1993-03-04
AU3401193A (en) 1993-09-09
KR930019637A (ko) 1993-10-18
HUT64041A (en) 1993-11-29
SK381192A3 (en) 1998-06-03
TW215434B (fr) 1993-11-01
PH31466A (en) 1998-11-03
NO303632B1 (no) 1998-08-10
NO930817D0 (no) 1993-03-05
HU9300618D0 (en) 1993-05-28
SK279109B6 (sk) 1998-06-03
CZ281983B6 (cs) 1997-04-16
CA2091135A1 (fr) 1993-09-08
NO930817L (no) 1993-09-08
JP3542813B2 (ja) 2004-07-14
AU663565B2 (en) 1995-10-12
CZ381192A3 (en) 1993-12-15
EP0560177B1 (fr) 2003-01-08
PL297955A1 (en) 1993-09-20
PL173023B1 (pl) 1998-01-30
CN1076192A (zh) 1993-09-15
MA22814A1 (fr) 1993-10-01
CN1036341C (zh) 1997-11-05
IL104971A0 (en) 1993-07-08
NZ247059A (en) 1995-03-28
BR9300761A (pt) 1993-09-14
EP0560177A1 (fr) 1993-09-15
US5604251A (en) 1997-02-18
ES2187501T3 (es) 2003-06-16
RU2116300C1 (ru) 1998-07-27
DK0560177T3 (da) 2003-04-14

Similar Documents

Publication Publication Date Title
IL104971A0 (en) Imidazole derivatives with a biphenylsulfonylurea or biphenylsulfonylurethane side chain,process for their preparation and their use
HUT62892A (en) Process for producing iso-and heterocyclic compounds furnished with imidazole ring and pharmaceutical compositions comprising same as active ingredient
RU93004577A (ru) Производные имидазола с боковой цепью бифенилсульфонилмочевины
PH30954A (en) Azole derivatives, process for their preparation and their use.
CA2064634A1 (fr) Derives de 9-desoxo-8a-aza-8a-homoerythromycine a modifies en positions 4"- et 8a
IL96882A0 (en) Uracil derivatives and pesticides containing the same as active ingredient
AU4755393A (en) Azaquinoxalines, processes for their preparation and their use
IL114894A0 (en) Endothelin antagonists
CA2371012A1 (fr) Imidazoles 4-(1h-pyrol-1-yl)
AU4149293A (en) 4-iminoquinolines, processes for their preparation, and their use
ZA929175B (en) 5,6-dihydro-dibenz(b,e)azepine-6,11-dione-11-oximes.
IT1255093B (it) Derivati imidazolidinonici come agenti nootropici